Glimepiride Accord Healthcare (Glimepiride)

Glimepiride Accord Healthcare is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, usually in combination with diet and exercise.

• Used as monotherapy when diet, exercise, and weight control are insufficient.
• Combined with other oral antidiabetic agents such as metformin to improve glycemic control.
• May be added to basal insulin therapy in patients who need additional glucose lowering.
• Considered for patients with stable renal function and no history of severe hypoglycemia.
• Prescribed to help achieve individualized HbA1c targets as part of a broader diabetes management plan.

The safety profile of glimepiride includes a range of adverse effects that vary in frequency and severity.

Common

• Mild hypoglycemia, especially when meals are missed or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Transient fatigue or weakness.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as rash, pruritus, or angio‑edema.
• Hematologic abnormalities including leukopenia or thrombocytopenia.
• Liver enzyme elevations indicating possible hepatic injury.
• Severe hypoglycemia requiring emergency medical attention.

Before initiating glimepiride therapy, clinicians should evaluate several patient‑specific factors to minimize risks.

• Assess renal and hepatic function; dose adjustment may be required in impairment.
• Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning.
• Caution in elderly patients due to increased susceptibility to hypoglycemia.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.
• Monitor for signs of hypoglycemia, especially when alcohol is consumed.
• Consider drug interactions that may potentiate glucose‑lowering effects.
• Educate patients on recognizing and managing low blood sugar episodes.

Glimepiride can interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia.
• Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which can raise glimepiride plasma levels.
• Discontinuation of corticosteroids or beta‑blockers without dose adjustment, leading to unexpected hypoglycemia.

Use with caution

• Anticoagulants (e.g., warfarin) – monitor INR as glimepiride may affect metabolism.
• Thiazide diuretics – may increase risk of hyperglycemia; monitor blood glucose.
• ACE inhibitors or ARBs – watch for renal function changes that could affect drug clearance.
• Alcohol – can potentiate hypoglycemic episodes; advise limited intake.